Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 8, 2015, Pages

  Hnin, Khin ^a   Nguyen, Chau ^b   Carson Chahhoud, Kristin V ^c   Evans, David J ^d   Greenstone, Michael ^e   Smith, Brian J ^b  

^a FLINDERS UNIVERSITY   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d Hemel Hempstead General Hospital   (United Kingdom)

^e CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; OXYTETRACYCLINE; PENICILLIN DERIVATIVE; PLACEBO; ROXITHROMYCIN; ANTIINFECTIVE AGENT;

ANOREXIA; ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BRONCHIECTASIS; BRONCHOSPASM; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC DISCOMFORT; ERYTHROCYTE SEDIMENTATION RATE; EXERCISE; FATIGUE; FEVER; FLATULENCE; FOOT EDEMA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HAND PARESTHESIA; HEART PALPITATION; HOSPITALIZATION; HUMAN; LEUKOCYTE COUNT; LUNG FIBROSIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SMOKING; SYSTEMATIC REVIEW; THORAX DISEASE; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VOMITING; ADULT; CHEMICALLY INDUCED; CHILD; DISEASE COURSE; META ANALYSIS; MICROBIOLOGY; MIDDLE AGED; ODDS RATIO; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

ADULT; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; CHILD; DIARRHEA; DISEASE PROGRESSION; DRUG RESISTANCE, BACTERIAL; HOSPITALIZATION; HUMANS; MIDDLE AGED; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 84991230612     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001392.pub3     Document Type: Review

References (320)

1. Altenburg J. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis. JAMA 2013;209(12):1251-9. 2681730
2. Altenburg J, de Graaff C, van der Werf T, Boersma W. Long-term azithromycin treatment: a randomised placebo-controlled trial in non-CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. 2011; Vol. 38. 2681729
3. Boersma WG, Altenburg J, Werf TS. Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2012;185:A3658. 2681731
4. Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2000;162(2 Pt 1):481-5. 2681733
5. Couch LA. Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest 2001;120(3):114S-17S. 2681734
6. Fiel SB. The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal 2000;16(Suppl 31):494s. 2681735
7. O'Donnell A, Tully H, Kylstra JW, Wells C, Schaeffler B, Barker AF. Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax 1999;54(Suppl 3):A68. 2681736
8. Currie DC, Garbett ND, Chan KL, Higgs E, Todd H, Nunn AJ, et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research 1987;72(Suppl 16):79P. 2681738
9. Currie DC, Garbett ND, Cole PJ. Double-blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine 1990;76(280):799-816. 2681739
10. Cymbala AA, Edmonds LC, Bauer MA, Jederlinic PJ, May JJ, Victory JM, et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine 2005;4(2):117-22. 2681741
11. De Diego A, Milara J, Martinez-Moragon E, Palop M, Leon M, Cortijo J. Effects of long-term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.) 2013;18(7):1056-62. 2681743
12. Drobnic ME, Sune P, Montoro JB, Ferrer A, Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Annals of Pharmacotherapy 2005;39(1):39-44. 2681745
13. Koh YY, Lee MH, Sun YH, Sung KW, Chae JH. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. European Respiratory Journal 1997;10(5):994-9. 2681747
14. Liu JF, Zhong XN, He ZY, Zhong DJ, Bai J, Zhang JQ, et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases] 2012;35(11):824-7. 2681749
15. Wu Q, Shen W, Cheng H, Zhou X. Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. Respirology 2014;19(3):321-9. 2681750
16. Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non-Tuberculous) Committee of the Medical Research Council. British Medical Journal 1957;2:255-9. 2681752
17. Antoniu SA, Trofor AC. Inhaled gentamicin in non-cystic fibrosis bronchiectasis: effects of long-term therapy. Expert Opinion on Pharmacotherapy 2011;12(7):1191-4. 2681754
18. Murray M, Govan J, Doherty C, Simpson A, Wilkinson T, Chalmers J, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2011;183:491-9. 2681755
19. Orriols R, Roig J, Ferrer J, Sampol G, Rosell A, Ferrer A, et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respiratory Medicine 1999;93(7):476-80. 2681757
20. Chen AC-H, Martin MM, Burr L, Hasnain SZ, Lourie R, Bowler SD, et al. Clinical benefits of long-term, low-dose erythromycin in bronchiectasis are not due to anti-inflammatory effects. American Thoracic Society International Conference; 2013 May 17-22; Philadelphia. 2013. 2681759
21. Serisier D, Martin M, McGuckin M, Lourie R, Chen A, Brain B, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis. JAMA 2013;309(12):1260-6. 2681760
22. Serisier DJ, Bowler SD, McGuckin M, Chen A, Lourie R, Martin ML. The Bronchiectasis and Low-dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine 2012;185:A6862. 2681761
23. Serisier DJ, Martin M. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology 2011;105(6):946-9. 2681762
24. Bruinenberg P, Serisier D, Blanchard J, Cipolla D, Gonda I. Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18-22; Barcelona. 2010. 2681764
25. Cipolla DC, Gonda I, Serisier D, Bruinenberg P. Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. 2681765
26. Serisier D, Kolbe J, Greville H, Gonda I, Bruinenberg P. Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non-cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13-18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. 2681766
27. Serisier DJ, Bilton D, De Soyza A, Thompson PJ, Kolbe J, Greville HW, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013;68:812-7. 2681767
28. Serisier DJ, Thompson PJ, Greville H, Kolbe J, Bruinenberg PR. Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non-cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13-18; Denver. 2011; Vol. 28:334s [1928]. 2681768
29. Tsang KW, Ho PI, Chan KN, Ip MS, Lam WK, Ho CS, et al. A pilot study of low-dose erythromycin in bronchiectasis. European Respiratory Journal 1999;13(2):361-4. 2681770
30. Tsang KW, Ho PL, Ho CS, Chan KN, Ip M, Lam WK, et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine 1998;157(Suppl 3):A174. 2681771
31. Mobberley C, Kake S, Faasalele H, Paterson J, Byrnes CA. Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology 2011;16(Suppl):TP-135. 2681773
32. Valery P, Morris PS, Byrnes CA, Grimwood K, Torzilla PJ, Bauert PA, et al. Long-term azithromycin for indigenous children with non-cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Lancet Respiratory Medicine 2013;1:610-20. 2681774
33. Valery PC, Morris PS, Grimwood K, Torzillo PJ, Byrnes CA, Masters BI, et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi-centre randomised controlled trial. BMC Pediatrics 2012;12:122-31. 2681775
34. Alder J, Wilson R, Welte T, Polverino E, De Soyza A, Greville H. Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. 2011. 2681777
35. Antoniu S, Azoicai D. Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs 2013;22(5):671-3. 2681778
36. Wilson R, Welte T, Polverino E, De Soyza A, Greville H, O'Donnell A, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal 2013;41(5):1107-15. 2681779
37. Wilson R, Welte T, Poverino E, Di Soyza A, Greville H, O'Donnell A. Randomized, placebo-controlled, double-blind, multi-center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non-cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2011;183:A6407. 2681780
38. Jayaran L, Wong CA, Karalus N, Eaton T, Tong C, Hockey H. Azithromycin decreases exacerbations in non-cystic fibrosis bronchiectasis. Respirology 2012;17:35. 2681782
39. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbation in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012;380:660-7. 2681783
40. Wong CA, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H. Azithromycin decreases exacerbations in non-cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2012;185:A3657. 2681784
41. Yalcin E, Kiper N, Ozcelik U, Dogru D, Firat P, Sahin A, et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics 2006;31(1):49-55. 2681786
42. Adachi F, Yamamoto K, Suzuki K, Yamamoto T. Preclinical and clinical studies on TE-031(A-56268) in elderly subjects. Chemotherapy 1988;36:660-6. 2681788
43. Takeda H, Oshitani H, Yondea Y, Kobayashi H. Basic and clinical studies on TE-031 (A-56268). [Japanese]. Chemotherapy 1988;36(Suppl 3):569-75. 2681789
44. Alberto S, Colongo PG, Brusasco L, Frigerio G. [Studies of the clinical and respiratory functional effects of a mucolytic-antibiotic preparation in chronic bronchopulmonary diseases. Controlled double-blind single code studies]. [Italian]. Minerva Medica 1968;59(53):2995-3002. 2681791
45. Alekseenko AV, Sokolov SB, Kobrin LI, Opalinskii VN, Lavrent'ev IuA. [Direct current in the overall treatment of inflammatory suppurative diseases of the lungs]. [Article in Russian]. Voprosy Kurortologii, Fizioterapii, i Lechebonoi Fizicheskoi Kultury 1978;2:44-6. 2681793
46. Allen MB, Fitzpatrick R. Amoxycillin with and without probenecid in the management of patients with bronchiectasis. Clinical Science 1988;74(Suppl 18):56P. 2681795
47. Allen MB, Fitzpatrick RW, Barratt A, Cole RB. The use of probenecid to increase the serum amoxycillin levels in patients with bronchiectasis. Respiratory Medicine 1990;84(2):143-6. 2681797
48. Al Mobeireek A, Kambal AM, Al Balla SR, Al Sawwaf H, Saleemi S. Pseudomonas aeruginosa in hospitalized patients with infective exacerbations of bronchiectasis: clinical and research implications. Annals of Saudi Medicine 1998;18(5):469-71. 2681799
49. Alora BD, Lloren PR. A comparative study between papase with tetracycline and tetracycline plain in the treatment of respiratory tract infections. Philippine Journal of Microbiology and Infectious Diseases 1978;7(1):7-16. 2681801
50. Anwar GA, Bourke SC, Afolabi G, Middleton P, Ward C, Rutherford RM. Effects of long-term low-dose azithromycin inpatients with non-CF bronchiectasis. Respiratory Medicine 2008;102:1494-6. 2681803
51. Barach AL, Bickerman HA, Beck GJ. Antibiotic therapy in infections of the respiratory tract. Archives of Internal Medicine 1952;90(6):808-49. 2681805
52. Begg EJ, Robson RA, Saunders DA, Graham CG, Buttimore RC, Neill AM, et al. The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing. British Journal of Clinical Pharmacology 2000;49(1):32-8. 2681807
53. Bergogne Berezin E, Berthelot G, Kafe H. Study of the diffusion of cefotiam in the bronchial secretions. Chemotherapy 1982;28(5):327-33. 2681809
54. Bergogne Berezin E, Berthelot G, Kafé HP, Dournovo P. Influence of a fluidifying agent (bromhexine) on the penetration of antibiotics into respiratory secretions. International Journal of Clinical Pharmacology Research 1985;5(5):341-4. 2681811
55. Bevilacqua M, Gironi G, Marinai E, Ulivieri P, Frigerio G. [Comparative study of the clinical activity of tetracycline and a combination of tetracycline and thiamphenicol in respiratory tract infections. Controlled study of a cooperative type]. [Italian]. Minerva Medica 1973;64(10):466-80. 2681813
56. Bilton D, Henig N, Morrissey B, Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006;130(5):1503-10. 2681815
57. Bilton D, Daviskas E, Anderson SD, Kolbe J, King G, Stirling RG, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013;144(1):215-25. 2681817
58. Bradley JM, Treacy K, O'Neill B, McCourt F, Green L, Gardner E, et al. A randomised double blind 13 week crossover trial of hypertonic saline(HTS) (6%) vs isotonic saline (ITS) (0.9%) in patients with bronchiectasis. Thorax 2011;66:A49 [S106]. 2681819
59. Brambilla C, Kastanakis S, Knight S, Cunningham K. Cefuroxime and cefuroxime axetil versus amoxicillin plus clavulanic acid in the treatment of lower respiratory tract infections. European Journal of Clinical Microbiology and Infectious Diseases 1992;11(2):118-24. 2681821
60. Bruninx M, De Koster JP, Golard P, Libert P, Minette A, Mottard L, et al. Prophylactic administration of Bactrim in chronic bronchitis: a double blind clinical and biological study. Acta Tuberculosea et Pneumologica Belgica 1973;64:483-501. 2681823
61. Brunix M, De Koster JP, Golard P, Libert P, Minette A, Mottard L, et al. Prophylactic administration of Bactrim in chronic bronchitis. A double blind clinical and biological study (author's transl). Acta Tuberculosea et Pneumologica Belgica 1974;64:483-501. 2681824
62. Chan TH, Ho SS, Lai CKW, Cheung SW, Chan RCY, Cheng AFB, et al. Comparison of oral ciprofloxacin and amoxycillin in treating infective exacerbations of bronchiectasis in Hong Kong. Chemotherapy 1996;42(2):150-6. 2681826
63. Chang KC, Leung CC, Yew WW, Lau TY, Leung WM, Tam CM, et al. Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis?. European Respiratory Journal 2010;35(3):606-13. 2681828
64. Chang AB, Grimwood K, Robertson CF, Wilson AC, van Asperen P, O'Grady KF, et al. Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo controlled trial. Trials 2012;13:156. 2681830
65. Cherniack NS, Vosti KL, Dowling HF, Lepper MH, Jackson GG. Long-term treatment of bronchiectasis and chronic bronchitis. AMA Archives of Internal Medicine 1959;103:345-53. 2681832
66. Cherniack NS, Carton RW. Factors associated with respiratory insufficiency in bronchiectasis. American Journal of Medicine 1966;41(4):562-71. 2681834
67. Choi YS, Kim YW, Yun SJ, Cho HK, Kim KH. A study about IgG subclass concentration of chronic cough patient and changes of immunoglobulin levels after RU 41.740 administration. Korean Journal of Pediatrics 1996;39:1385-94. 2681836
68. Chonabayashi N, Yoshimura K, Nakatani T, Nakamori Y, Nakata K, Tanimoto H, et al. Clinical study of TE-031 (A-56268) in the treatment of 17 patients with respiratory infections [Japanese]. Chemotherapy 1988;36(Suppl 3):586-93. 2681838
69. Chonabayashi N, Yoshimura K, Nakatani T, Nakamori Y, Nakata K, Tanimoto H, et al. Clinical studies of T-3262 in respiratory tract infection [Japanese]. Chemotherapy 1988;36(Suppl 9):694-8. 2681840
70. Chuchalin AG, NovikovIu K, Avdeev SN, Belevski AS. [Effectiveness of ciprofloxacin in the treatment of hospital infections of the lower respiratory tract]. Antibiotiki i Khimioterapiia [Antibiotics and Chemotherapy] 1997;42(6):34-8. 2681842
71. Clarke CS, Rawal BD. Co-trimoxazole-ascorbic acid in the treatment of chronic Pseudomonas aeruginosa infection of the lower respiratory tract. Journal of Antimicrobial Chemotherapy 1981;7(3):311-2. 2681844
72. Crowther Labiris NR1, Holbrook AM, Chrystyn H, Macleod SM, Newhouse MT. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study. American Journal of Respiratory and Critical Care Medicine 1999;160(5 Pt 1):1711-6. 2681846
73. Cseri T, Kelemen S. Treatment with Sumetrolim in chronic non-specific respiratory tract infections. Therapia Hungarica 1975;23(3):115-7. 2681848
74. Currie DC, Gargett ND, Cole PJ. Penetration of antibiotics into the respiratory tract. British Medical Journal 1987;295(6590):119. 2681850
75. Czako K, Schnitzler J, Nagy M. Surgical results in primary bronchiectasis. Zeitschrift fur Tuberkulose und Erkrankungen der Thoraxorgane 1968;129(3):153-6. 2681852
76. Danesi R, Del Tacca M. Clinical study on the efficacy of clofoctol in the treatment of infectious respiratory diseases. International Journal of Clinical Pharmacology Research 1985;5(3):175-9. 2681854
77. Davies BI, Maesen FP, van Noord JA. Treatment of chronic and recurrent respiratory infections with intramuscular ceftazidime. Journal of Antimicrobial Chemotherapy 1983;12(Suppl A):1-8. 2681856
78. Dobrev P, Maksimov Vl, Tafradzhiiska M, Nikolova P, Popov B. Giramid in lung diseases. Pnevmologiya i Ftiziatriya 1990;27(4):27-30. 2681858
79. Douglas AC, Somner AR, Marks BL, Grant IWB. Effect of antibiotics on purulent sputum in chronic bronchitis and bronchiectasis. Lancet 1957;273(6988):214-8. 2681860
80. Doutsu Y, Inoue Y, Masaki M, Masuyama Y, Yamashita K, Mashimoto H, et al. Laboratory and clinical studies on NY-198 [Japanese]. Chemotherapy 1988;36(Suppl 2):II. 2681862
81. Finegold SM, Gentry LO, Mogabgab W, Campbell SC, Skatrud J. Controlled comparative trial of bacampicillin and amoxicillin in therapy of bacterial infections of the lower respiratory tract. Reviews of Infectious Diseases 1981;3(1):150-3. 2681864
82. Foweraker JE, Cooke NH, Hawkey PM. Ecology of Haemophilus influenzae and Haemophilus parainfluenzae in sputum and saliva and effects of antibiotics on their distribution in patients with lower respiratory tract infections. Antimicrobial Agents and Chemotherapy 1993;37(4):804-9. 2681866
83. Franklin AW, Garrod LP. Chloramphenicol treatment of bronchiectasis in children. British Medical Journal 1953;2:1067-9. 2681868
84. Garcia Rodriquez JA, Gomez Garcia AC. A comparison of cefotaxime and cefoperazone in respiratory tract infections. Journal of Antimicrobial Chemotherapy 1984;14(Suppl B):301-6. 2681870
85. Grau S, Saballs P, Drobnic L, Del Villar A, Salas E, Monterde J, et al. Substitution of cefamandol by cefonicid. A prospective study of use according to protocol. Revista Espanola de Quimioterapia 1992;5(4):337-42. 2681872
86. Haidl P, Bargon J, Gessler T, Pfeifer M, Randerath W, Voshaar T, et al. Effect of inhalation of tobramycin for 12 months on reduction of hospitalisation rate in severe COPD. Pneumologie 2013;67(9):514-9. 2681874
87. Hara K, Kohno S, Kadota JI, Kazunori T, Yoichi H, Shigefumi M, et al. Clinical investigation of ciprofloxacin IV in severe and/or refractory infections in the internal medicine field. Japanese Journal of Chemotherapy 1997;45(11):923-35. 2681876
88. Harada S, Harada Y, Kitahara Y, Takamoto M, Ishibashi T, Shinoda A. Ampicillin in lower respiratory tract infections [Japanese]. Chemotherapy 1988;36(Suppl 8):237-43. 2681878
89. Hayashi T, Yamada H, Tasuoka A, Sasayama K, Doutsu Y, Kohno S, et al. Basic and clinical studies on cefdinir [Japanese]. Chemotherapy 1989;37(Suppl 2):565-78. 2681880
90. Helm WH, May JR, Livingstone JL. Long-term oxytetracycline (terramycin) therapy in advanced chronic respiratory infections. Lancet 1956;1:775-7. 2681882
91. Hernandez C, Abreu J, Jimenez A, Fernandez R, Martin C. Pulmonary function and quality of life in relation to bronchial colonization in adults with bronchiectasis not caused by cystic fibrosis. Medicina Clinica 2002;118(4):130-4. 2681884
92. Hill SL, Burnett D, Hewetson KA, Stockley RA. Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses orally or by inhalation. Thorax 1986;41(7):559-65. 2681886
93. Hill SL, Morrison HM, Burnett D, Stockley RA. The response of patients with purulent bronchiectasis to antibiotics for four months. Quarterly Journal of Medicine 1988;66(250):163-73. 2681888
94. Hill SL, Bilton D, Johnson MM, Pye A, Mitchell JL, Stockley RA. Sputum and serum pharmacokinetics of loracarbef (a new carbacephem antibiotic) in patients with bronchiectasis [Abstract]. European Respiratory Journal 1992;5(Suppl 15):142s. 2681890
95. Hill SL, Bilton D, Johnson MM, Pye A, Mitchell JL, Stockley RA. Sputum and serum pharmacokinetics of loracarbef (LY163892) in patients with chronic bronchial sepsis. Journal of Antimicrobial Chemotherapy 1994;33(1):129-36. 2681892
96. Hossain A, Ahamed M, Sharkar ZH. Change in clinical outcome of exacerbation of bronchiectasis on addition of nebulised gentamicin to systemic antibiotics. Congress of the Asian Pacific Society of Respirology; 2010; 22-25 Nov; Manila. 2010. 2681894
97. Howie JG. Antibiotics and purulent sputum. British Medical Journal 1976;2(6040):882. 2681896
98. Hughes DT. Use of combinations of trimethoprim and sulphamethoxazole in the treatment of chest infections. Medical Journal of Australia 1973;1(2 Suppl):58-61. 2681898
99. Hughes DT. Use of combinations of trimethoprim and sulfamethoxazole in the treatment of chest infections. Journal of Infectious Diseases 1973;128(Nov Suppl):701-5. 2681900
100. Ida S, Shindoh Y, Takishima T. Antimicrobial activity and clinical evaluation of NY-198. [Japanese]. Chemotherapy 1988;36(Suppl 2):II. 2681902
101. Iino Y, Sugita K, Toriyama M, Kudo K. Erythromycin therapy for otitis media with effusion in sinobronchial syndrome. Archives of Otolaryngology 1993;119(6):648-51. 2681904
102. Inoue Y, Masuyama Y, Dotsu Y, Kaku M, Suyama N, Hayashi T, et al. Basic and clinical studies on 7432-S. [Japanese]. Chemotherapy 1989;37(Suppl 1):285-97. 2681906
103. Ip M, Shum D, Lauder I, Lam WK, So SY. Effect of antibiotics on sputum inflammatory contents in acute exacerbations of bronchiectasis. Respiratory Medicine 1993;87(6):449-54. 2681908
104. Ip M, Tsang K, Chan WM, Ho PL, Lam B, Lam WK. Randomised controlled study of levofloxacin versus ceftazidime in acute exacerbations of bronchiectasis. American Journal of Respiratory and Critical Care Medicine 1998;157(3 Suppl):A173. 2681910
105. Irabu Y, Tamaki K, Fukuhara H, Nakamura H, Kaneshima H, Shimoij K, et al. Laboratory and clinical studies on cefdinir. [Japanese]. Chemotherapy 1989;37(Suppl 2):603-11. 2681912
106. Irabu Y, Fukuhara H, Nakamura H, Kaneshima H, Simoji K, Kitsukawa K, et al. Laboratory and clinical studies of ME1207. [Japanese]. Chemotherapy 1992;40(Suppl 2):452-8. 2681914
107. Izumi S. Clinical studies of tazobactam/piperacillin in respiratory tract infection. Chemotherapy 1994;42(Suppl 2):716-8. 2681916
108. Izumikawa K, Koteda T, Sakamoto Y, Sawatari K. Basic and clinical studies on TE-031 (A-56268) in treatment of respiratory tract infections [Japanese]. Chemotherapy 1988;36(Suppl 3):729-36. 2681918
109. Jia B, Lu P, Huang W, Li C, Huang A, Zhou X, et al. A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections. Chemotherapy 2010;56(4):285-90. 2681920
110. Kaji M, Saito A, Shimada J, Ohmori M, Shiba K, Yamaji T, et al. Clinical studies on NY-198. [Japanese]. Chemotherapy 1988;36(Suppl 2):II. 2681922
111. Kanai J, Tanaka S, Matsumoto T, Noda S. Clinical trial use of phenoxypropyl penicillin. Journal of Antibiotics 1963;16:25-6. 2681924
112. Karachalios GN. Treatment of respiratory tract infections with a combination of amoxycillin and clavulanic acid. International Journal of Clinical Pharmacology, Therapy, and Toxicology 1985;23(12):647-9. 2681926
113. Kawai S, Kawahira M, Oshitani H, Kobayashi H. NY-198 in the treatment of respiratory infections. [Japanese]. Chemotherapy 1988;36(Suppl 2):II. 2681928
114. Nakatani T, Noguchi M, Yoshimura K, Nakamori Y, Chonabayashi N, Nakata K, et al. Clinical trial with NY-198 against respiratory tract infections. [Japanese]. Chemotherapy 1988;36(Suppl 2):II. 2681929
115. Kawai S, Sakayori S, Kobayashi H. Clincial study on NM441 in respiratory tract infections. [Japanese]. Japanese Journal of Chemotherapy 1996;44:594-6. 2681931
116. Kawano M, Irimajiri K, Higuchi J, Uchiyama T, Tsubura E. Studies on amikacin (BB-K8), a new aminoglycoside antibiotic (author's transl). Japanese Journal of Antibiotics 1974;27(4):446-50. 2681933
117. Kawashima K, Yamamoto H, Kadoya M, Kato M, Nata T, Iida E, et al. Clinical role of Branhamella catarrhalis infection in pulmonary disorders. [Japanese]. Saishin Igaku [Modern Medicine] 1989;44(6):1268-72. 2681935
118. Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respiratory Medicine 2011;105:1831-5. 2681937
119. Kikuchi N1, Kawashima T, Yamagishi F, Suzuki K, Yasuda J, Niijima Y, et al. Clinical evaluation of ciprofloxacin in pulmonary infections in the patients with chronic respiratory diseases. Japanese Journal of Antibiotics 1991;44(8):839-45. 2681939
120. Knox K, Elmes PC, Fletcher CM. Chronic bronchitis: an attempt to control chronic infection by Haemophilus Influenzae by aerosol therapy. Lancet 1955;268(6855):120-2. 2681941
121. Kobayashi H, Takamura K, Kono K, Onodera S, Sasaki N, Nagahama F, et al. Comparison of DL-8280 and amoxicillin in the treatment of respiratory tract infections. Journal of the Japanese Association for Infectious Diseases 1984;58(6):525-55. 2681943
122. Kobayashi H, Takeda H, Watanabe H, Ohtami H, Sakayori S. Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine. Japanese Journal of Chemotherapy 1995;43(Suppl 1):333-51. 2681945
123. Koh YY, Park Y, Jeong JH, Kim CK, Min YG, Chi JG. The effect of regular salbutamol on lung function and bronchial responsiveness in patients with primary ciliary dyskinesia. Chest 2000;117(2):427-33. 2681947
124. Koyama M. ME1207: a clinical study. [Japanese]. Chemotherapy 1992;40(Suppl 2):692-5. 2681949
125. Krawczyk Z, Gornicka Wilczynska M, Pilarska Machowicz A, Pruszynska S. Comparative evaluation of certain antibiotics and Biceptol preparation in the treatment of chronic bronchial disease exacerbations. [Polish]. Polski Tygodnik Lekarski 1981;36(25):927-30. 2681951
126. Krofton DV. [Chemotherapy of respiratory diseases]. [Russian]. Antibiotiki 1971;16(8):743-9. 2681953
127. Kudo K, Komase Y, Kowada A, Kabe J. Preclinical and clinical studies on TE-031 (A-56268) in treatment of bacterial respiratory tract infections. [Japanese]. Chemotherapy 1988;36(Suppl 3):617-22. 2681955
128. Kudo K, Ishii A, Kabe J. ME1207 in respiratory infections. [Japanese]. Chemotherapy 1992;40(Suppl 2):696-9. 2681957
129. Kulpati DDS, Sahai S. Anaerobes in pleuropulmonary infections. Journal International Medical Sciences Academy 1990;3(1):13-9. 2681959
130. Kurasawa T, Kuze F, Kato M, Yamamoto K, Ikeda N, Matsubara T, et al. NY-198 in the treatment of respiratory infections. [Japanese]. Chemotherapy 1988;36(Suppl 2):II. 2681961
131. Kurishima S, Hirose H, Fukui T, Katsu M. Basic and clinical studies on cefclidin. [Japanese]. Chemotherapy 1992;40(Suppl 4):273-9. 2681963
132. Kuze F, Kurasawa T, Kato M, Kagioka A, Inaba N, Kuroda N, et al. Cefodizime (THR-221) in respiratory tract infections. [Japanese]. Chemotherapy 1988;36(Suppl 5):467-72. 2681965
133. Lam WK, Chau PY, So SY, Leung YK, Chan JC, Sham MK, et al. A double-blind randomized study comparing ofloxacin and amoxicillin in treating infective episodes in bronchiectasis. Infection 1986;14(Suppl 4):S290-2. 2681967
134. Lam WK1, Chau PY, So SY, Leung YK, Chan JC, Ip M, Sham MK. Ofloxacin compared with amoxycillin in treating infective exacerbations in bronchiectasis. Respiratory Medicine 1989;83(4):299-303. 2681969
135. Lam PK, Griffith DE, Aksamit TR, Ruoss SJ, Garay SM, Daley CL, et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. American Journal of Respiratory and Critical Care Medicine 2006;173(11):1283-9. 2681971
136. Lamotte A. Bronchiectasis. [French]. Ouest-Medical 1981;34(14):969-72. 2681973
137. Ledson MJ, Cowperthwaite C, Walshaw MJ, Gallagher MJ, Williets T, Hart CA. Nebulised taurolidine and B cepacia bronchiectasis. Thorax 2000;55(1):91-2. 2681975
138. Lin HC, Wang CH, Liu CY, Yu CT, Kuo HP. Amoxicillin down-regulates the release of neutrophil derived pro-inflammatory cytokines and C5a in patients with bronchiectasis. European Respiratory Journal 1996;9(23):400s. 2681977
139. Lin HC, Wang CH, Liu CY, Yu CT, Kuo HP. Erithromycin upregulates β2-Integrins (CD11B/CD118) expression and intracellular oxidant capacity in airway neurophils of patients with bronchiectasis. European Respiratory Journal 1996;23(Suppl 9):400s. 2681978
140. Lin HC, Cheng HF, Wang CH, Liu CY, Yu CT, Kuo HP. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. American Journal of Respiratory and Critical Care Medicine 1997;155(6):2024-9. 2681980
141. Lin JT, Yu XZ, Cui DJ, Chen XY, Zhu JH, Wang YZ, et al. A multicenter randomized controlled study of the efficacy and safety of oseltamivir in the treatment of influenza in a high risk population. [Chinese]. Chinese Journal of Tuberculosis and Respiratory Diseases 2004;27(7):455-9. 2681982
142. Lin JT, Yu XZ, Cui DJ, Chen XY, Zhu JH, Wang YZ, et al. A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population. Current Medical Research and Opinion 2006;22(1):75-82. 2681983
143. Lioberes P, Barber E, Montserrat JM, Picado C. Intermittent antibiotic treatment in patients with stable bronchiectasis: a comparative study between amoxycillin and cefonicid [abstract]. European Respiratory Journal Supplement 1990;3(Suppl 10):88S. 2681985
144. Lunacharskaia TV, Kopeiko IP. Intratracheal use of morphocycline. [Russian]. Antibiotiki 1968;13(12):1123-6. 2681987
145. Maekawa N, Tsukuma S, Nakanishi M, Yamashita M, Kanda M. Clinical results of the use of cephaloridine in lung diseases, especially pulmonary tuberculosis. [Japanese]. Journal of Antibiotics [B] 1967;20(2):140-4. 2681989
146. Mahashur AA, Chaudhuri RA, Bowalekar SK, Raghu CN. Pefloxacin in the treatment of nosocomial respiratory tract infections. Current Therapeutic Research, Clinical and Experimental 1993;54(4):437-42. 2681991
147. Mahashur AA, Pal M, Parikh HS, Karkera SG, Kukreja A. Study of the efficacy of immunomodulator imunocin, as an add-on therapy in the management of patients with chronic obstructive pulmonary disorder and bronchiectasis. Indian Practitioner 2002;55(6):393-9. 2681993
148. Masekela R, Anderson R, Gongxeka H, Steel HC, Becker PJ, Green RJ. Lack of efficacy of an immunomodulatory macrolide in childhood. Journal of Antivirals & Antiretrovirals 2013;5(2):044-9. 2681995
149. Masuno T, Ikeda T, Kishimoto S, Morimoto Y, Tsujimoto T, Igarashi T, et al. A clinical study of cefclidin [Japanese]. Chemotherapy 1992;40(Suppl 4):331-40. 2681997
150. Matsumoto K, Harada T, Shishido H. Laboratory and clinical evaluation on ceftazidime with the special reference to respiratory infections caused by Pseudomonas aeruginosa. Chemotherapy 1983;31(Suppl 3):434-47. 2681999
151. Matsumoto K, Chung HY, Hsieh WC. Asian multicenter trial of cefoperazone in respiratory tract infection. Clinical Therapeutics 1984;6(6):824-38. 2682001
152. Matsumoto K, Nagatake T, Shishido H. Laboratory and clinical evaluation of lenampicillin (KBT-1585) in respiratory infection. [Japanese]. Chemotherapy 1984;32(Suppl 8):397-411. 2682003
153. Matsumoto K, Takahashi A, Yamamoto M. A study on the evaluation of the efficacy of chemotherapy for chronic respiratory tract infections. [Japanese]. Chemotherapy 1986;34(4):316-30. 2682005
154. Matsumoto M, Koga Y, Ando M, Araki S. Clinical studies on ME1207 in the treatment of respiratory tract infections. [Japanese]. Chemotherapy 1992;40(Suppl 2):740-3. 2682007
155. Matsushima T, Ikeda H, Adachi M, Tomisawa S, Kawanishi M, Tanabe J, Tano Y. Clinical study of NY-198 in pulmonary infections. [Japanese]. Chemotherapy 1988;36(Suppl 2):II. 2682009
156. Matsuura T, Suzuki K, Yamamoto T. Clinical studies of S-1108 in elderly patients. Chemotherapy 1993;41(Suppl 1):795-9. 2682011
157. Matzeu M, Mancini PA, Parola D. The use of sisomicin in chronic bronchopulmonary disorders. Drugs Under Experimental and Clinical Research 1981;7(4):503-6. 2682013
158. May JR, Ingold A. Amoxycillin in the treatment of chronic non-tuberculous bronchial infections. British Journal of Diseases of the Chest 1972;66(3):185-91. 2682015
159. May JR, Ingold A. Amoxicillin in the treatment of infections of the lower respiratory tract. Journal of Infectious Diseases 1974;129(Suppl):S189-93. 2682017
160. May JR, Ingold H. Amoxicillin in the treatment of lower respiratory infections. Advances in Clinical Pharmacology 1974;7:85-90. 2682018
161. Mazzei JA, Vujacich P, Fernandez A, Tanco J. Ciprofloxacin in the treatment of lower respiratory tract infections. Drugs 1993;46(Suppl 3):407-9. 2682020
162. McVay LV Jr, Sprunt DH. Antibiotic prophylaxis in chronic respiratory diseases. Archives of Internal Medicine 1953;92(6):833-46. 2682022
163. Mehta AP, Phutane L, Patel MH, Rupwate RU, Kamat SR. Comparative study of amoxycillin and amoxycillin/clavulanic acid in lower respiratory infections. Journal of the Association of Physicians of India 1991;39(3):251-3. 2682024
164. Messens Y, Oger A, Cornette M, Calay G. [Double-blind study of the sulfamethoxazole-trimethoprim association in the treatment of pulmonary infections]. Acta Clinica Belgica 1973;28(2):92-9. 2682026
165. Mijuskovic B, Macanovic J. Bisolvomycin and Bisolvon in the treatment of chronic bronchitis, bronchial asthma and bronchiectasis. Plucne Bolesti i Tuberkuloza 1972;24(3):229-33. 2682028
166. Milcev M, Ovcarova H, Ivanov S. Antibacterial treatment of anaerobic lung infections. [Bulgarian]. Pnevmologiya i Ftiziatriya 1985;22(3):20-4. 2682030
167. Min KY. Clinical evaluation of TE-031 in the chronic respiratory infections. [Japanese]. Japanese Pharmacology and Therapeutics 1988;16(7):335-47. 2682032
168. Minami H, Sakai S, Shimokata K. Combination regimen of low dose erythromycin and ofloxacin against chronic airway infections. Japanese Journal of Chest Diseases 1996;55(10):845-50. 2682034
169. Ming O, Yong L, Zhang W. Efficacy of macrolide and theophylline in the management of bronchiectasis [Abstract]. Respirology (Carlton, Vic) 2005;10(Suppl 3):A168. 2682036
170. Miyamoto Y, Horiuchi T, Wantanabe T. Experience with AT-2266. [Japanese]. Chemotherapy 1984;32(Suppl 3):441-7. 2682038
171. Molodtsova VP, Fedoseev GB, Gerasin VA. [Cleansing of the bronchial tree in treating chronic inflammatory lung disease]. [Russian]. Sovetskaia Meditsina 1980;11:90-2. 2682040
172. Morrone N, Saito M, Brito VC, Hayashi F. Pulmonary infections in adults: two therapeutics regimens of ofloxacin. A Folha Médica 1989;98(4):253-8. 2682042
173. Murayama T, Kuze F, Oida K, Nanbu Y, Iwata T, Ikeda N, et al. A clinical study of the effects of ME1207 on respiratory infections. [Japanese]. Chemotherapy 1992;40(Suppl 2):724-7. 2682044
174. Music E, Kumelj M, Prlja D, Paulin A, Potokar T. Comparison of amoxicillin and amoxiclav in the therapy of respiratory infections. Plucne Bolesti: Casopis Udruzenja Pneumoftiziologa Jugoslavije [Journal of Yugoslav Association of Physiology and Pneumology] 1989;41(3-4):187-92. 2682046
175. Nagy M, Meszaros G. [Late results of the conservative treatment of bronchiectasis in adults]. [German]. Zeitschrift fur Tuberkulose und Erkrankungen der Thoraxorgane 1968;127(5):283-90. 2682048
176. Nakagawa M, Tsubura E. Clinical study of S-1108 in respiratory infections. Chemotherapy 1993;41(Suppl 1):803-6. 2682050
177. Nakagawa Y, Niki Y, Hino J, Kishimoto T, Kawane H, Soejima R. Clinical effect of balofloxacin in respiratory tract infections. [Japanese]. Japanese Journal of Chemotherapy 1995;43(Suppl 5):547-9. 2682052
178. Nakamori Y, Tsuboi E, Narui K, Nakatani T, Sugi H. Sputum penetration of levofloxacin and its clinical efficacy in patients with chronic lower respiratory tract infections. [Japanese]. Japanese Journal of Antibiotics 1992;45(5):539-47. 2682054
179. Nakamura M, Hasegawa N, Miyao N, Nakajima T, Terashima T, Sakamaki F, et al. [Comparison of 5 day short-course therapies for secondary infection in patients with chronic respiratory disease using gatifloxacin and levofloxacin]. Japanese Journal of Chemotherapy 2007;55(6):451-62. 2682056
180. Nakatani T, Tsuboi E, Narui K, Nakamori Y, Nakata K, Sugi H. Clinical efficacy of temafloxacin in respiratory infections and its pharmacokinetics in sputum. Chemotherapy 1993;41(Suppl 5):361-8. 2682058
181. Nasu M, Yamazaki T, Yamazaki H, Kuroda Y, Goto J, Tashiro T, et al. T-3262 in respiratory tract infections. [Japanese]. Chemotherapy 1988;36(Suppl 9):699-709. 2682060
182. Neumayr A, Stoeffler G. Clinical trials of the new antibiotic, rifamycin sv: preliminary report. Chemotherapy 1963;12:437-8. 2682062
183. Nobuoka T, Kobayashi Y, Fujimori I. Clinical study on BAY o 9867 in the field of internal medicine. [Japanese]. Chemotherapy 1985;33(Suppl 7):373-9. 2682064
184. O'Donovan C, Rudd R, O'Neill S, Fitzgerald MX, McNicholas W, Flavell-Matts SG, et al. Augmentin (intravenous then oral) compared with cefuroxime followed by cephalexin for chest infections in hospitalised patients. British Journal of Clinical Practice 1987;41(12):1044-52. 2682066
185. Oishi K, Sonoda F, Kobayashi S, Iwagaki A. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infection and Immunity 1994;62(10):4145-52. 2682068
186. Oizumi K, Wantanabe A, Konno K, Hayashi I, Kawamorida K, Nagai K, et al. [Therapeutic effect of amikacin for infections with gram-negative bacilli, especially for stubborn respiratory infections (author's transl)]. [Japanese]. Japanese Journal of Antibiotics 1978;31(1):15-23. 2682070
187. Oki Y, Morishita M, Miyachi A. An evaluation of low dose long term erythromycin chemotherapy in bronchiectasis. Japanese Journal of Chest Diseases 1993;52(1):54-8. 2682072
188. Ovcharenko SI, Loginov LE, Zavodnov Ya V. Antibiotic therapy of bronchial pyoinflammation using endobronchial low-frequency ultrasound. [Russian]. Klinicheskaia Meditsina 1991;69(9):29-31. 2682074
189. Patterson JE, Bradley JM, Hewit O, Bradbury I, Elborn JS. Airway clearance during oral antibiotic therapy in bronchiectasis, a randomized trial of acapella versus usual airway clearance [Abstract]. American Thoracic Society 2005 International Conference; May 20-25; San Diego, California. 2005:B25; Poster: 917. 2682076
190. Patterson JE, Hewitt O, Kent L, Bradbury I, Elborn JS, Bradley JM. Acapella versus 'usual airway clearance' during acute exacerbation in bronchiectasis: a randomized crossover trial. Chronic Respiratory Disease 2007;4(2):67-74. 2682078
191. Pezza A, Giacomelli P, Montella R, Casino G. [Clinical study of a new cephalosporin: ceftriaxone (RO 13-9904) in resurgent acute and chronic bronchopneumopathies]. [Italian]. Archivio Monaldi per la Tisiologia e le Malattie dell'Apparato Respiratorio 1983;38(1-2):17-24. 2682080
192. Pines A, Raafat H, Khorasani M, Mullinger BM. Cephaloridine compared with penicillin and streptomycin in chronic purulent bronchitis. Controlled trials of increasing dosage of cephaloridine. British Journal of Diseases of the Chest 1967;61(2):101-10. 2682082
193. Pines A, Raafat H. Cefuroxime in severe respiratory infections: a double-blind comparison of two doses. British Journal of Diseases of the Chest 1979;73(4):395-8. 2682084
194. Pines A, Raafat H, Plucinski K, Greenfield JS, Linsell WD. Cefuroxime and ampicillin compared in a double-blind study in the treatment of lower respiratory tract infections. Chemotherapy 1981;27(6):459-65. 2682086
195. Piovano CF, Palombini BC, Dagrosa EE, Mendoza F, Facco EB. Cefodizime once daily in the treatment of lower respiratory tract infections. Arzneimittel-Forschung 1997;47(5):674-7. 2682088
196. Popov B, Kalfin EM. Peflacin - clinical study in patients with pulmonary diseases. [Bulgarian]. Pnevmologiya i Ftiziatriya 1988;25(3):30-5. 2682090
197. Prigogine T, Glupczynski Y, Carpiaux JP, Blogie M, Yourassowsky E, Schmerber JS. Enoxacin in acute exacerbations of chronic bronchitis: a comparison with amoxycillin. Journal of Antimicrobial Chemotherapy 1988;21(Suppl B):131-6. 2682092
198. Ramer P, Medici TC, Hatt RR, Unger S, Ronner B. [Trimethoprim-sulfamethoxazole versus amoxycillin in the therapy of acute bacterial exacerbations in chronic non-specific respiratory tract diseases: a controlled study]. Schweizerische Medizinische Wochenschrift 1981;111(48):1823-9. 2682094
199. Rayner CFJ, Tillotson G, Cole PJ, Wilson R. Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis. Journal of Antimicrobial Chemotherapy 1994;34(1):149-56. 2682096
200. Rimoldi R, Fioretti M, Bandera M. Use of miocamycin in respiratory infection. Annali dell'Istituto Superiore di Sanita 1987;23(4):891-4. 2682098
201. Saito A, Kusano N, Fukuhara H, Soejima R, Nakahama C, Niki Y, et al. A study of the clinical effects of clindamycin on respiratory infections - Focusing on inhibition of beta-lactamase production. [Japanese]. Chemotherapy 1993;41(11):1232-45. 2682100
202. Saito A, Ohmichi M, Arakawa M, Wada K, Tsukada H, Iwata F, et al. Dose-finding study of gatifloxacin, a new oral, quinolone, in chronic respiratory tract infection. [Japanese]. Japanese Journal of Chemotherapy 1999;47(Suppl 2):419-37. 2682102
203. Saito A. Clinical studies of gatifloxacin for infections in internal medicine. Japanese Journal of Chemotherapy 2002;50(10):646-73. 2682104
204. Santiveri C, Orriols R, Roig J, Balcells E, Bellver P, Ferrer A, et al. Effectiveness of inhaled antibiotic treatment for Pseudomonas aeruginosa in outpatients with colonized bronchiectasis without mucoviscidosis [Abstract]. Archivos de Bronconeumologia 1995;31(Suppl):42. 2682106
205. Sawae Y, Kashiwagi S, Kumagai Y, Ishimaru T, Takii M, Shigeoka H, et al. Clinical studies on the utility of ofloxacin for lower respiratory infections. Japanese Journal of Antibiotics 1991;44(1):48-57. 2682108
206. Sawae Y, Ninomiya K, Takaki K, Shimono N, Misumi H, Okada K. A comparative study of ofloxacin twice and three times daily in the treatment of respiratory tract infections. Drugs 1995;49(Suppl 2):430-2. 2682110
207. Sawaki M, Mikami R, Mikasa K, Kunimatsu M, Ito S, Narita N. The long term chemotherapy with erythromycin in chronic lower respiratory tract infections: first report - comparing with amoxicillin. Japanese Association of Infectious Disease 1986;60(1):37-44. 2682112
208. Schulz G. [Comparative studies on the toxicity of tetracyclines and chloramphenicol in the treatment of nonspecific bronchopulmonary infections]. [German]. Zeitschrift fur Erkrankungen der Atmungsorgane mit Folia Bronchologica 1972;136(2):185-96. 2682114
209. Serisier DJ, Martin ML. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respiratory Medicine 2011;105(6):946-9. 2682116
210. Serisier DJ, Martin M, Bowler SD. Research bronchoscopic biopsy in adult bronchiectasis subjects is associated with significant bleeding risk. Respirology 2011;16(Suppl):62 [TP-100]. 2682118
211. Shrewsbury SB, Bilton D, Gotfried M, Jones SA. [The TABLE study (TOBI in acute bronchiectasis: additional treatment for exacerbations): rationale and methology]. American Thoracic Society 100th International conference; 2004 May 21-26; Orlando. Orlando, 2004:A42 Poster A53. 2682120
212. Shigeno Y, Masaki M, Nakazato H. Laboratory and clinical studies on lenampicillin (KBT-1585) a new penicillin antibiotic. [Japanese]. Chemotherapy 1984;32(Suppl 8):382-96. 2682122
213. Shimada K, Oka S, Saito A, Tomizawa M, Hiraga Y, Ohmichi M, et al. A dose-finding study on pazufloxacin in chronic respiratory tract infections. Japanese Journal of Chemotherapy 1996;44(4):231-47. 2682124
214. Shimada K, Inamatsu T, Fukayama M, Kato A, Adachi K, Sasaki M, et al. Antimicrobial activity and clinial evaluation of NY-198. Chemotherapy 1988;36(Suppl 2):701-12. 2682126
215. Shimokata K, Kawazu H, Nishiwaki K, Yamamoto M, Sakai S, Senda Y. Evaluation of imipenem/cilastatin sodium in the treatment of respiratory tract infections. Japanese Journal of Antibiotics 1990;43(1):14-22. 2682128
216. Shimokata K, Sakai S, Senda Y, Nishiwaki K, Yamaoto M, Murate T, et al. Evaluation of cefclidin on respiratory tract infections. Chemotherapy 1992;40(Suppl 4):748-52. 2682130
217. Shirai T, Sato A, Chida K. Effect of 14-membered ring macrolide therapy on chronic respiratory tract infections and polymorphonuclear leukocyte activity. Internal Medicine 1995;34(6):469-74. 2682132
218. Shishido H, Takasugi M, Uzuka Y, Takahashi A, Akiyama M, Hirose H, et al. Sultbactam.ampicillin (1:2) in respiratory tract infections with special reference to beta-lactamase-producing organisms. Chemotherapy 1988;36(Suppl 8):257-72. 2682134
219. Shishido H, Furukawa K, Nagai H, Kawakami K, Kono H. Oral levofloxacin 600mg and 300mg daily doses in difficult-to-treat respiratory infections. Drugs 1995;49(Suppl 2):433-5. 2682136
220. IInternational Collaboration of Bronchiectasis Network, Singleton R, Morris P, Leach A, Roseby R, White A, et al. Multicentre bronchiectasis study; a collaboration and international study of bronchiectasis in indigenous children [Abstract]. Respirology (Carlton, Vic) 2007;12(Suppl 4):A192. 2682138
221. Singleton R, Morris P, Leach A, Roseby R, White A, Valery P, et al. Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children [Abstract]. Respirology (Carlton, Vic) 2008;13(Suppl 2):A19. 2682140
222. Soejima R, Niki Y, Hino J, Nakagawa Y, Sumi M, Kishimoto T, Matsumoto A. Clinical studies on TE-031 (A-56268). Chemotherapy 1988;36(Suppl 3):673-8. 2682142
223. Stass H, Nagelschmitz J, Kappeler D, Weimann B. Lung deposition of ciprofloxacin dry powder for inhalation in healthy subjects and patients suffering from chronic obstructive pulmonary disease or non-cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2013;187(Meeting Abstracts):A1507. 2682144
224. Stockley RA, Hill SL, Burnett D. Effect of antibiotic treatment on sputum elastase in bronchiectatic outpatients in a stable clinical state. Thorax 1984;39(6):414-9. 2682146
225. Stockley RA, Hill SL, Morrison HM. Nebulized amoxicillin in chronic purulent bronchiectasis. Clinical Therapeutics 1985;7(5):593-9. 2682148
226. Suga M, Ando M, Tanaka F, Ito K, Aakata T, Sugimoto M, Araki S. Clinical studies of T-3262 in respiratory tract infection. [Japanese]. Chemotherapy 1988;36(Suppl 9):694-8. 2682150
227. Suyama N, Inoue Y, Masaki M, Mashimoto H, Masuyama Y, Dohtsu Y, et al. Laboratory and clinical studies on cefodizime (THR-221). Chemotherapy 1988;36(Suppl 5):529-44. 2682152
228. Tagaya E, Tamaoki A, Kondo M, Nakada J, Nagai A. [Effect and action mechanism of short-term administration of calrithromycin for airway hypersecretion]. [Japanese]. Japanese Journal of Antibiotics 2001;54(Suppl A):33-5. 2682154
229. Tagaya E, Tamaoki J, Kondo M, Nagai A. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest 2002;122(1):213-8. 2682155
230. El-Din MA, Palmer LB, El-Tayeb MN, Khalil I, Gabr MS. Nebulizer therapy with antibiotics in chronic suppurative lung disease. Journal of Aerosol Medicine 1994;7(4):345-50. 2682157
231. Takamoto M, Ishibashi T, Toyoshima H, Tanaka H, Tamaru N, Watanabe K, et al. Imipenem/cilastatin sodium alone or combined with amikacin sulfate in respiratory infections. Japanese Journal of Antibiotics 1994;47(9):1131-44. 2682159
232. Tamura S, Tokita K, Tsutsumi Z, Ohkawa T, Fujioka H, Kurabori J, et al. Clinical studies on cefclidin [Japanese]. Chemotherapy 1992;40(Suppl 4):737-7. 2682161
233. Tanimoto H, Obara K, Komatuzaki K, Tanabe O, Okamura T. A clinical study on ME1207 in respiratory infections. Chemotherapy 1992;40(Suppl 2):683-5. 2682163
234. Tanimoto H, Obara K, Tateishi O, Okamura T. Clinical studies on S-1108 in respiratory infections. Chemotherapy 1993;41(Suppl 1):751-4. 2682165
235. Taskar VS, Sharma RR, Goswami R, John PJ, Mahashur AA. Effect of bromhexeine on sputum amoxycillin levels in lower respiratory infections. Respiratory Medicine 1992;86(2):157-60. 2682167
236. Tsang KT, Roberts P, Read R, Coles SJ, Wilson R, Cole PJ. The concentration of clarithromycin and its active 14-hydroxy metabolite in sputum of patients with bronchiectasis following single dose oral administration. British Journal of Clinical Pharmacology 1993;35:84P. 2682169
237. Tsang KWT, Roberts P, Read RC, Kees R, Wilson R, Cole PJ. The concentrations of clarithromycin and its 14-hydroxy metabolite in sputum of patients with bronchiectasis following single dose oral administration. Journal of Antimicrobial Chemotherapy 1994;33(2):289-97. 2682171
238. Tsang KW, Chan WM, Ho PL, Chan K, Lam WK, Ip MS. A comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis. European Respiratory Journal 1999;14(5):1206-9. 2682173
239. Unoura T, Masuda M, Takeuchi K, Itoh T, Tamura M, Ykui T, et al. Clinical study on TE-031 (A56268) against respiratory infections. Chemotherapy 1988;36(Suppl 3):544-8. 2682175
240. Vergnon JM, Vincent M, Ros A, Brun Y, Brune J. Comparative clinical trial of cefoperazone vs ampicillin + tobramycin in severe bronchopulmonary and pleural infectious pathology. Revue di Pneumologie Clinique 1985;41(3):205-11. 2682177
241. Watanabe K, Hibino J, Ikemoto H. Clinical trials of netilmicin against respiratory tract infection. Japanese Journal of Antibiotics 1982;35(8):1907-10. 2682179
242. Watanabe A, Oizumi K, Aonuma S, Ono R, Honda Y, Tokue Y, et al. In vitro antimicrobial activity of 7432-S and its therapeutic efficacy in chronic respiratory tract infections. Chemotherapy 1989;37(Suppl 1):148-57. 2682181
243. Watanabe A. Once daily versus every two week multidose ofloxacin in patients with acute exacerbations of chronic respiratory disease. Infection 1991;19(Suppl 7):S384-7. 2682183
244. Watanabe A, Motomiya M, Nukiwa T, Nakai Y, Honda Y, Konno K, et al. A well-controlled comparative clinical study of the combination regimen of ciprofloxacin plus erythromycin for the treatment of repeated acute exacerbations of chronic respiratory tract infections. [Japanese]. Chemotherapy 1994;42(10):1194-201. 2682185
245. Watanabe A, Oizumi K, Motomiya M, Nukiwa T. Daily single-dose regimen and alternate-two-week triple-dose/day regimen of oral ofloxacin for the prophylaxis and control of exacerbations of chronic respiratory tract infections. Tohoku Journal of Experimental Medicine 1995;176(1):25-33. 2682187
246. Watanabe A, Kohno S, Niki Y, Saito A. Comparison of chest X-ray findings and other parameters in acute exacerbation of chronic bronchitis in Japan and the West. Journal of Infection and Chemotherapy 2001;7(1):37-44. 2682189
247. Yamada H, Katoh O, Aoki Y, Nakata H, Yamaguchi M. Clinical study on S-1108 in respiratory tract infections. Chemotherapy 1993;41(Suppl 1):816-9. 2682191
248. Yamaki K, Takagi K, Suzki R, Sumita T, Gonda H, Satake T, et al. T-3262 in respiratory tract infection and effect on blood theophylline concentration. Chemotherapy 1988;36(Suppl 9):567-74. 2682193
249. Young WK, Yeon MO, Man PJ, Chul GY, Sung KH, Young SS, et al. The effect of low-dose longterm erythromycin on bronchiectasis. Tuberculosis and Respiratory Diseases 1993;40(4):390-4. 2682195
250. Zhang JJ. Observations on the effect of sodium fosfomycin on the lower respiratory tract infection. Chinese Journal of Antibiotics 2003;28(6):361-3. 2682197
251. Aksamit T, Bandel TJ, Criollo M, De Soyza A, Elborn JS, Operschall E, et al. The RESPIRE trials: two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis. Contemporary clinical trials. United States, 2017; Vol. 58:78-85. 6614748
252. Alder J, Hampel B, Reimnitz P, Wilson R. Correlation of bacterial species and density at baseline to exacerbations requiring antibiotic treatment in a phase 2 trial of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo in patients with non-cystic fibrosis bronchiectasis. American journal of respiratory and critical care medicine. American Thoracic Society, 2012; Vol. 185. 6614750
253. Altenburg J, Wilms E, Boersma W. The relationship between serum-and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie (stuttgart, germany). Georg Thieme Verlag, 2016; Vol. 70, issue 10. 6614752
254. Altenburg J, Wolf R, Go S, van Rijn P, Boersma W, van der Werf T. Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European respiratory journal 2016; Vol. 48, issue Suppl 60:OA278. 6614754
255. Altenburg J, Wolf R, Go S, Van Rijn P, Boersma W, Van Der Werf T. Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European respiratory journal. Conference: european respiratory society annual congress 2016. United kingdom. European Respiratory Society, 2016; Vol. 48, issue no pagination. 6614756
256. Barker AF, O'Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. The Lancet. Respiratory medicine. England: Lancet Publishing Group, 2014; Vol. 2, issue 9:738-49. 6614758
257. Burr L, Rogers G, Taylor S, Mcguckin M, Serisier D. Sub inhibitory erythromycin reduces the expression of key p. aeruginosa virulence determinants in non-CF bronchiectasis subjects. Respirology (Carlton, Vic.). Blackwell Publishing, 2015; Vol. 20, issue Suppl 2:29 [TO 043]. 6614760
258. Burr LD, Rogers GB, Chen AC, Hamilton BR, Pool GF, Taylor SL, et al. Macrolide Treatment Inhibits Pseudomonas aeruginosa Quorum Sensing in Non-CF Bronchiectasis: an Analysis from the BLESS Trial. Annals of the american thoracic society 2016; Vol. 13, issue 10:1697-703. 6614762
259. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. American journal of respiratory and critical care medicine 2012; Vol. 186, issue 7:657-65. 6614764
260. Chang AB, Grimwood K, Wilson AC, van Asperen PP, Byrnes CA, O'Grady KF, et al. Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial. BioMed Central 2013;14:53-63. 2682199
261. Chen A, Martin M, Lourie R, Burr L, Hasnain S, Bowler S, et al. Clinical benefits of long-term, low-dose erythromycin in bronchiectasis are not due to modulation of sputum mucin content [Abstract]. Respirology (Carlton, Vic.). Blackwell Publishing, 2014; Vol. Conference: 2014 Annual Scientific Meetings of the Thoracic Society of Australia and New Zealand and the Australian and New Zealand Society of Respiratory Science Adelaide, SA Australia. Conference Start: 20140404 Conference End: 20140409. Conference Publication:, issue var.pagings:88 [TP 093]. 6614766
262. De Soyza A, Aksamit TR, Bandel T-J, Criollo M, Elborn J S, Krahn U, et al. RESPIRE 1: ciprofloxacin DPI 32.5mg b.d. administered 14 day on/off or 28 day on/off vs placebo for 48 weeks in subjects with non-cystic fibrosis bronchiectasis (NCFB). European respiratory journal 2016; Vol. 48, issue Suppl 60:OA272. 6614768
263. Dimakou K, Triantafillidou C, Tsikritsaki K, Gousiou A, Dervas A, Toumbis M. Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa [Abstract]. European respiratory journal 2014; Vol. 44, issue Suppl 58:P244. 6614770
264. Hare KM, Grimwood K, Chang AB, Chatfield MD, Valery PC, Leach AJ, et al. Nasopharyngeal carriage and macrolide resistance in Indigenous children with bronchiectasis randomized to long-term azithromycin or placebo. European journal of clinical microbiology & infectious diseases. Germany: Springer Verlag, 2015; Vol. 34, issue 11:2275-85. 6614772
265. Haworth C, Bilton D, Kenyon R. Nebulised colistimethate sodium improves quality of life in patients with bronchiectasis colonised by Pseudomonas aeruginosa [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7-11; Barcelona. 2013; Vol. 42:577s [P2732]. 2682201
266. Haworth C, Bilton D, Kenyon R. Nebulised colistimethate sodium improves quality of life in patients with bronchiectasis colonised by pseudomonas aeruginosa [Abstract]. 2013; Vol. 42:577s [P2732]. 6614774
267. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. American journal of respiratory and critical care medicine. United States: American Thoracic Society, 2014; Vol. 189, issue 8:975-82. 6614776
268. Juthong S, Eiamsa-ard S. The effects of roxithromycin as anti-inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam. 2011; Vol. 38:819s [4496]. 2682203
269. Kobbernagel HE, Buchvald FF, Haarman EG, Casaulta C, Collins SA, Hogg C, et al. Study protocol, rationale and recruitment in a European multi-centre randomized controlled trial to determine the efficacy and safety of azithromycin maintenance therapy for 6 months in primary ciliary dyskinesia. BMC pulmonary medicine. England: BioMed Central Ltd., 2016; Vol. 16, issue 1) (no pagination:104. 6614778
270. Liu JF, Zhong XN, He ZY, Zhong DJ, Bai J, Zhang JQ, et al. Impact of treatment with low dose roxithromycin on stable. Zhonghua jie he he hu xi za zhi [Chinese journal of tuberculosis and respiratory diseases] 2012;35(11):824-7. 6614780
271. Liu J, Zhong X, He Z, Wei L, Zheng X, Zhang J, et al. Effect of low-dose, long-term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of inflammation. United States, 2014; Vol. 2014:708608. 6614782
272. Lourdesamy Anthony AI, Muthukumaru U. Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.). Australia: Blackwell Publishing, 2014; Vol. 19, issue 8:1178-82. 6614784
273. Corrections to The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fi brosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet respiratory medicine. United Kingdom: Lancet Publishing Group, 2015; Vol. 3, issue 4:e15. 6614786
274. O'Donnell AE, Bilton D, Serisier D, Wanner A, Froehlich J, Bruinenberg P, et al. ORBIT-3 and ORBIT-4: design of a Phase 3 Program to Investigate Safety and Efficacy of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (NCFBE) Patients Chronically Colonized with Pseudomonas Aeruginosa (PA). American journal of respiratory and critical care medicine 2016; Vol. 193, issue Meeting Abstracts:A1775. 6614788
275. O'Donnell A, Bilton D, Serisier D, Wanner A, Froehlich J, Bruinenberg P, et al. A phase 3 study design of Pulmaquin in non-cystic fibrosis bronchiectasis (NCFBE) patients chronically colonized with pseudomonas aeruginosa (PA). Pneumologie. Conference: 1st world bronchiectasis conference. Germany. Conference start: 20160707. Conference end: 20160709. Georg Thieme Verlag, 2016; Vol. 70, issue 10) (no pagination. 6614790
276. Orriols R, Hernando R, Ferrer A, Terradas S, Montoro B. Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis. Respiration; international review of thoracic diseases. Switzerland: S. Karger AG, 2015; Vol. 90, issue 4:299-305. 6614792
277. Rogers GB, Bruce KD, Martin ML, Burr LD, Serisier DJ. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.[Erratum appears in Lancet Respir Med. 2015 Apr;3(4): e15; PMID: 25890660]. The Lancet. Respiratory medicine. England: Lancet Publishing Group, 2014; Vol. 2, issue 12:988-96. 6614794
278. Tabernero E, Gil P, Alkiza R, Garros J, Hernandez A, Artola JL. Inhaled colistin in elderly patients with non-cystic fibrosis. Chest 2014;145(3 Suppl):431A. 6614796
279. Tabernero Huguet E, Gil Alana P, Alkiza Basanez R, Hernandez Gil A, Garros Garay J, Artola Igarza JL. Inhaled colistin in elderly patients with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa bronchial infection]. [Spanish. Revista espanola de geriatria y gerontologia 2015;50(3):111-5. 6614798
280. Terpstra L, Altenburg J, Boersma W. Effects of long term tobramycin inhalation solution (TIS) once daiLy on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. A doubleblind, randomized, placebo controlled trial. The BATTLE study. Pneumologie. Conference: 1st world bronchiectasis conference. Germany. Conference start: 20160707. Conference end: 20160709. Georg Thieme Verlag, 2016; Vol. 70, issue 10) (no pagination. 6614800
281. Twiss J, Byrnes C. Nebulized antibiotics reduce symptoms, bacterial density and oral antibiotic usage in children with non-cystic fibrosis bronchiectasis. 2009 Thoracic Society of Australia & New Zealand (TSANZ) and Australian & New Zealand Society of Respiratory Science (ANZSRS) Annual Scientific Meeting; 2009 3-8 April; Darwin. Darwin, Australia, 2009; Vol. 14:A76. 2682205
282. Twiss J, Byrnes CA. Nebulized antibiotics reduce symptoms, bacterial density and oral antibiotic usage in children with non-cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2008 May 16-21; Toronto. Toronto, 2008:A681 [#C40]. 2682206
283. Yalcin E, Kiper N, Ozcelik U, Dogru D, Firat P, Sahin A, et al. Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of clinical pharmacy and therapeutics 2006;31(1):49-55. 6614802
284. Australian Institute of Health and Welfare. Asthma, chronic obstructive pulmonary disease and other respiratory diseases in Australia. http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442453795 (accessed 13 November 2014). [URL: http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442453795 [date accessed 18/07/2014]]
285. Angrill J, Agusti C, De Celis R, Filella X, Rano A, Elena M, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2001;164:1628-32.
286. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2012;186(7):657-65.
287. Chalmers JD, Goeminne P, Aliberti S, McDonnel M, Lonni S, Davidson J, et al. The Bronchiectasis Severity Index. An international derivation and validation study. American Journal of Respiratory and Critical Care Medicine 2013;189:576-85.
288. Chang A, Grimwood K, Mulholland E, Torzillo P. Bronchiectasis in indigenous children in remote Australian communities. Medical Journal of Australia 2002;177:200-4.
289. Cole PJ. Inflammation: a two-edged sword-the model of bronchiectasis. European Journal of Respiratory Diseases Supplement 1986;147:6-15.
290. Downey DG, Brockbank S, Martin SL, Ennis M, Elborn JS. The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatric Pulmonology 2007;42(8):729-35.
291. Goeminne PC, Nawrot TS, Ruttens D, Seys S, Dupont LJ. Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respiratory Medicine 2014;108(2):287-96.
292. Grimwood K. Airway microbiology and host defences in paediatric non-CF bronchiectasis. Paediatric Respiratory Reviews 2011;12:111-8.
293. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
294. Hill AT, Campbell EJ, Hill SL, Bayley D, Stockley RA. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. American Journal of Medicine 2000;109:288-95.
295. King PT. The pathophysiology of bronchiectasis. International Journal of Chronic Obstructive Pulmonary Disease 2009;4:411-9.
296. Kwak HJ. High prevalence of bronchiectasis in adults: analysis of CT findings in a health screening program. The Tohoku Journal of Experimental Medicine 2010;222:237-42.
297. Lee YM. The clinical characteristics of patients with non-CF bronchiectasis. Chest 2011;140:459A.
298. Loebinger M. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. European Respiratory Journal 2009;34(4):843-9.
299. Maguire G. Bronchiectasis: a guide for primary care. Australian Family Physician 2012;41:842-50.
300. Martinez-Garcia MA, de Gracia J, Vendrell RM. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. European Respiratory Journal 2014;43:1357-67.
301. Martínez García M, Máiz Carro L, Catalán Serra P. Treatment of non-cystic fibrosis bronchiectasis. Archivos de Bronconeumologia 2011;47:599-609.
302. McShane PJ, Naureckas ET, Tino G, Strek ME. Non-cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2013;188:647-56.
303. O'Donnell AE. Bronchiectasis. Chest 2008;134(4):815-23.
304. Ordonez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2003;168(12):1471-5.
305. Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65:i1-i58.
306. Reid LM. Reduction in bronchial subdivision in bronchiectasis. Thorax 1950;5:233-47.
307. Sagel SD, Kapsner R, Osberg I, Sontag MK, Accurso FJ. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. American Journal of Respiratory and Critical Care Medicine 2011;164:1425-31.
308. Saleh A, Hurst J. How to assess the severity of bronchiectasis. European Respiratory Journal 2014;45:1217-9.
309. Saynajakangas O, Keistinen T, Tuuponen T, Kivela SL. Evaluation of the incidence and age distribution of bronchiectasis from the Finnish hospital discharge register. Central European Journal of Public Health 1998;6:235-7.
310. Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots R. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000 to 2007. Chest 2012;142:432-9.
311. Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respiratory Medicine 2013;1:262-74.
312. Serisier DJ. The evidence base for non-CF bronchiectasis is finally evolving. Respirology 2014;19(3):295-7.
313. Tunney M. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. American Journal of Respiratory and Critical Care Medicine 2013;187(10):1118-26.
314. Twiss J, Metcalfe R, Edwards E, Byrnes C. New Zealand national incidence of bronchiectasis "too high" for a developed country. Archives of Disease in Childhood 2005;90:737-40.
315. Valery P, Morris P, Grimwood K, Torzillo P, Byrnes C, Masters IB, et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled trial. BMC Paediatrics 2012;12:122.
316. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clinical Pulmonary Medicine 2005;12:205-9.
317. Wilson R, Hansell DM, Loebinger MR. Definition and aetiology of non-CF bronchiectasis. In: Blasi F, Miravitlles M editor(s). The Spectrum of Bronchial Infection. Sheffield: European Respiratory Society, 2013:107-19. [ISBN: 978-1-84984-034-7 ]
318. Wu Q, Shen W, Cheng H, Zhou X. Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. Respirology 2014;19(3):321-9.
319. Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD001392]
320. Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD001392.pub2]